TIRZ 60MG LY-3298176

Tirzepatide is a synthetic, dual-incretin peptide designed as a pharmacological agent for the management of type 2 diabetes mellitus and obesity. It functions as a balanced agonist of both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R), leveraging the complementary physiological actions of these incretins. Activation of GLP-1R enhances glucose-dependent insulin secretion, suppresses postprandial glucagon release, and delays gastric emptying, while GIPR agonism further potentiates insulinotropic effects and may contribute to improved adipose tissue metabolism. Clinical trials have demonstrated that tirzepatide produces significant reductions in HbA1c, fasting glucose levels, and body weight in a dose-dependent manner, exceeding the efficacy observed with selective GLP-1 receptor agonists. Pharmacokinetic studies indicate a prolonged half-life compatible with once-weekly subcutaneous administration, promoting patient adherence. Current research continues to investigate long-term cardiovascular safety, potential benefits on non-alcoholic fatty liver disease, and mechanistic contributions of dual receptor engagement to weight loss and metabolic homeostasis, with attention to minimizing adverse effects such as gastrointestinal intolerance and hypoglycemia.